Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04235257 · ClinicalTrials.gov registry record · Phase 4
Intradermal, Fractional Dose of HPV Vaccines:
A Phase 4 study of HPV Infection and HPV Vaccine, sponsored by University of Washington.
- Active
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT04235257 is a Phase 4 study of HPV Infection and HPV Vaccine that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 40 participants, below the 233-participant average among 13 other HPV Infection trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04235257, a Phase 4 study of HPV Infection and HPV Vaccine, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized phase IV trial compares fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, 12 months, and 24 months.
Conditions Studied
Interventions
- BIOLOGICAL HPV vaccine
Study Locations (1)
Washington
- University of Washington Virology Research Clinic - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04235257
The ClinicalTrials.gov registry entry for NCT04235257 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 233-participant average among 13 other HPV Infection trials with a reported enrollment target (83% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HPV Infection appearing as the primary indexed condition, and to 1 intervention - of which HPV vaccine is the first listed.
NCT04235257 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT04235257 about?
NCT04235257 is a clinical study titled "Intradermal, Fractional Dose of HPV Vaccines:". This randomized phase IV trial compares fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, 12 months, and 24 months.
What is the current status of trial NCT04235257?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2020-11-01. Estimated completion is 2026-12-31.
What conditions does trial NCT04235257 study?
This clinical trial studies the following conditions: HPV Infection, HPV Vaccine.
What interventions are being tested in trial NCT04235257?
The interventions under investigation include: HPV vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04235257?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04235257 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Immunogenicity of Fractional Dose of the HPV Vaccines
ACTIVE NOT RECRUITING · Phase 4
-
An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
ACTIVE NOT RECRUITING · Phase 4
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
PCOM2 - The Physician Communication Intervention, Version 2.0
RECRUITING · NA
-
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.